Beranda › Limfoma Non-Hodgkin
Uji klinis Limfoma Non-Hodgkin yang merekrut di AS
127 studi untuk Limfoma Non-Hodgkin merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX31 studi
- New York City, NY31 studi
- Boston, MA26 studi
- Nashville, TN21 studi
- Philadelphia, PA20 studi
- Baldwin Park, CA19 studi
- Atlanta, GA18 studi
- Chicago, IL18 studi
- Columbus, OH18 studi
- Milwaukee, WI18 studi
- Washington, DC18 studi
- Dallas, TX17 studi
- Durham, NC16 studi
- Seattle, WA16 studi
- Portland, OR15 studi
- Rochester, MN14 studi
- Miami, FL14 studi
- Omaha, NE14 studi
- Denver, CO14 studi
- Cleveland, OH13 studi
- Salt Lake City, UT13 studi
- Mountain View, CA12 studi
- St. Louis, MO11 studi
- Aurora, CO11 studi
- Los Angeles, CA9 studi
- Tampa, FL9 studi
- Jacksonville, FL9 studi
- Cincinnati, OH9 studi
- San Francisco, CA9 studi
- Pittsburgh, PA8 studi
- San Diego, CA8 studi
- Baltimore, MD8 studi
- Ann Arbor, MI8 studi
- Cedar Rapids, IA8 studi
- Clifton, NJ7 studi
- Buffalo, NY7 studi
- Kansas City, MO7 studi
- Edison, NJ7 studi
- Birmingham, AL7 studi
- Queens, NY7 studi
Berdasarkan negara bagian
- Alabama7 studi
- Arizona14 studi
- Arkansas5 studi
- California42 studi
- Colorado20 studi
- Connecticut8 studi
- Delaware4 studi
- Distrik Columbia4 studi
- Florida32 studi
- Georgia21 studi
- Hawaii3 studi
- Idaho3 studi
- Illinois20 studi
- Indiana10 studi
- Iowa10 studi
- Kansas9 studi
- Kentucky5 studi
- Louisiana6 studi
- Maine4 studi
- Maryland21 studi
- Massachusetts28 studi
- Michigan13 studi
- Minnesota19 studi
- Mississippi3 studi
- Missouri10 studi
- Montana3 studi
- Nebraska15 studi
- New Jersey13 studi
- New Mexico4 studi
- New York40 studi
- North Carolina24 studi
- North Dakota3 studi
- Ohio34 studi
- Oklahoma3 studi
- Oregon15 studi
- Pennsylvania26 studi
- Rhode Island5 studi
- South Carolina5 studi
- South Dakota3 studi
- Tennessee24 studi
- Texas48 studi
- Utah14 studi
- Virginia13 studi
- Washington20 studi
- West Virginia3 studi
- Wisconsin20 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Menerima pesertaFase 1
Hingga usia 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Menerima pesertaFase 1
Usia 12 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Menerima pesertaFase 1
Usia 12 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Menerima pesertaFase 1/2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Menerima pesertaFase 2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Menerima pesertaFase 1
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05798897Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.